| アブストラクト | OBJECTIVE: Previous studies evaluating the effect of metformin on cancer risk have been impacted by time-related biases. To avoid these biases, we examined the incidence of bladder cancer in new users of metformin and sulfonylureas (SUs). RESEARCH DESIGN AND METHODS: This cohort study included 87,600 patients with type 2 diabetes in The Health Improvement Network database. Use of metformin or an SU was treated as a time-dependent variable. Cox regression-generated hazard ratios (HRs) compared metformin use with SU use, adjusted for age, sex, smoking, obesity, and HbA1c level. RESULTS: We identified 196 incident bladder cancers in the metformin cohort and 66 cancers in the SU cohort. Use of metformin was not associated with decreased bladder cancer risk (HR 0.81 [95% CI 0.60-1.09]). This association did not differ by sex (P for interaction = 0.20). We observed no association with duration of metformin relative to SU use (3 to <4 years of use: 0.57 [0.25-1.34]; 4 to <5 years of use: 0.93 [0.30-2.85; >/=5 years of use: 1.18 [0.44-3.19]; P for trend = 0.26). CONCLUSIONS: Use of metformin is not associated with a decreased incidence of bladder cancer. Similar methods should be used to study other cancers that have previously been identified as potentially preventable with metformin. |
|---|
| ジャーナル名 | Diabetes care |
|---|
| Pubmed追加日 | 2014/2/6 |
|---|
| 投稿者 | Mamtani, Ronac; Pfanzelter, Nick; Haynes, Kevin; Finkelman, Brian S; Wang, Xingmei; Keefe, Stephen M; Haas, Naomi B; Vaughn, David J; Lewis, James D |
|---|
| 組織名 | Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;ronac.mamtani@uphs.upenn.edu.;Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.;Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania,;Philadelphia, PA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/24496803/ |
|---|
